Novartis gets creative in pricing next-generation cancer therapy
Its medicine is for a severe form of cancer in young people, known as acute lymphoblastic leukaemia
London
NOVARTIS AG, set to beat Kite Pharma Inc to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.
The US Food and Drug Administration is likely to rule in early October on the experimental treatment called CTL019, Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said in an interview. The regulator is due to decide on Kite's product, designed for a different type of blood cancer, by November 29.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Blackstone-led consortium eyes snacks business of India’s Haldiram’s: sources
Cordlife shareholders vote to remove 3 directors, including co-founder Ho Choon Hou, from board
Walmart to lay off hundreds of corporate staff and relocate others: WSJ
Haidilao restaurant operator Super Hi targets US$1.38 billion valuation in US IPO
Cordlife to cancel private placement; MOH stresses importance of local directors
GameStop soars as flag bearer ‘Roaring Kitty’ resurfaces, sparks meme stock rally